C
Centro De Dermatologia De Monterrey | Monterrey, Mexico
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
CP-690,550
PF-04965842
Ritlecitinib
MSB11022
Dupilumab
Upadacitinib
Abrocitinib
Povorcitinib
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 10 total trials
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo
Locations recently updated
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems